BioZen Limited

Developing the world’s first approved medical cure for moobs!

OWNER

Ilan Chaitowitz (See Profile)

Sector

Biotech

Stage

Development, market readiness, clinical trial

Country

United Kingdom

First-in-class approved cure for gynecomastia that of all males and side-effect of androgen blockade for prostate cancer

Proven management team along with strategic partnership with Syneos Health who anticipate >$350m annual peak sales

Strong IP position covering both method of use and formulation - global rights and long duration

Compelling return profile - proof-of-concept scheduled to read out within three years

Low clinical risk using known molecules with synergistic MoA

Patent

Status

Pending

IP Type

Patent

Time

–

Countries

Australia

Austria

Belgium

Canada

China

Denmark

Finland

France

Germany

Israel

Italy

Netherlands

Switzerland

USA

United Kingdom

Coverage

Method of use and formulation for gynecomastia.

Know more of this patent

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

Other files:

BioZen White Paper

Prevail Partners Term Sheet

Syneos Health Commercial Feasibility Study

Paediatric Gynecomastia: Review of Pharmacological Treatments

Tamoxifen for breast events induced by antiandrogens in patients with prostate cancer

EAA clinical practice guidelines - gynecomastia evaluation and management

Under evaluation at least till: 1st of October 2023

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

Funding: 5.000.000$
Stage: Development, market readiness, clinical trial
Sector: Biotech
+

BioZen Limited

BioZen Limited Developing the world's first approved medica...
Funding: 500.000€
Stage: Development, market readiness, clinical trial
Sector: Medical Device
+

Laboratorios Isimo, SL

Laboratorios Isimo, SL Laboratorios Isimo, SL Medical Devic...

OWNER

Sector

Stage

Country

First-in-class approved cure for gynecomastia that of all males and side-effect of androgen blockade for prostate cancer

Proven management team along with strategic partnership with Syneos Health who anticipate >$350m annual peak sales

Strong IP position covering both method of use and formulation - global rights and long duration

Compelling return profile - proof-of-concept scheduled to read out within three years

Low clinical risk using known molecules with synergistic MoA

This information is confidential, do not share or copy.

BioZen Limited

Laboratorios Isimo, SL

Capital Cell Barcelona

Links

About cookies

OWNER

Sector

Stage

Country

First-in-class approved cure for gynecomastia that of all males and side-effect of androgen blockade for prostate cancer

Proven management team along with strategic partnership with Syneos Health who anticipate >$350m annual peak sales

Strong IP position covering both method of use and formulation - global rights and long duration

Compelling return profile - proof-of-concept scheduled to read out within three years

Low clinical risk using known molecules with synergistic MoA

This information is confidential, do not share or copy.

BioZen Limited

Laboratorios Isimo, SL

Capital Cell Barcelona

Links

About cookies

Log in with your credentials

Forgot your details?

Create Account